Abstract
The aim of this work was to synthesize a series of compounds to study their antimycobacterial potential. Eight compounds were found to be most active with minimum inhibitory concentration of less than 6μM and were more active than Isoniazid (INH) against Mycobacterium tuberculosis H37Rv (MTB). Compounds with electron withdrawing group substituted on the aryl ring were showing better activity. Among the fifteen newly synthesized compounds, compound 6- methyl-4-(4-nitrophenyl)-2-oxo-N-(pyridin-2-yl)-1,2,3,4tetrahydropyrimidine-5-carboxamide (B) was found to be the most active agent against MTB and INH resistant Mycobacterium tuberculosis (INHR-MTB) with minimum inhibitory concentration of <0.35 μM.
Keywords: Antimycobacterial, Biginelli, Dihydropyrimidine, One pot, Mycobacterium tuberculosis, multidrug-resistant TB, antituberculosis activity, nitroimidazoles, antitubercular activities
Letters in Drug Design & Discovery
Title:Antimycobacterial Agents: Synthesis and Biological Evaluation of Novel 4-(Substituted-phenyl)-6-methyl-2-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine- 5-carboxamide Derivatives by Using One-pot Multicomponent Method
Volume: 9 Issue: 10
Author(s): Abdulrahman I. Almansour, Mohamed Ashraf Ali, Sadath Ali, Ang Chee Wei, Yeong Keng Yoon, Rusli Ismail, Tan Soo Choon, Suresh Pandian, Raju Suresh Kumar, Natarajan Arumugam and Hasnah Osman
Affiliation:
Keywords: Antimycobacterial, Biginelli, Dihydropyrimidine, One pot, Mycobacterium tuberculosis, multidrug-resistant TB, antituberculosis activity, nitroimidazoles, antitubercular activities
Abstract: The aim of this work was to synthesize a series of compounds to study their antimycobacterial potential. Eight compounds were found to be most active with minimum inhibitory concentration of less than 6μM and were more active than Isoniazid (INH) against Mycobacterium tuberculosis H37Rv (MTB). Compounds with electron withdrawing group substituted on the aryl ring were showing better activity. Among the fifteen newly synthesized compounds, compound 6- methyl-4-(4-nitrophenyl)-2-oxo-N-(pyridin-2-yl)-1,2,3,4tetrahydropyrimidine-5-carboxamide (B) was found to be the most active agent against MTB and INH resistant Mycobacterium tuberculosis (INHR-MTB) with minimum inhibitory concentration of <0.35 μM.
Export Options
About this article
Cite this article as:
I. Almansour Abdulrahman, Ashraf Ali Mohamed, Ali Sadath, Chee Wei Ang, Keng Yoon Yeong, Ismail Rusli, Soo Choon Tan, Pandian Suresh, Suresh Kumar Raju, Arumugam Natarajan and Osman Hasnah, Antimycobacterial Agents: Synthesis and Biological Evaluation of Novel 4-(Substituted-phenyl)-6-methyl-2-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine- 5-carboxamide Derivatives by Using One-pot Multicomponent Method, Letters in Drug Design & Discovery 2012; 9 (10) . https://dx.doi.org/10.2174/1570180811209050953
DOI https://dx.doi.org/10.2174/1570180811209050953 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
Current Pharmaceutical Design Biological Evaluation of Halogenated Thioureas as Cholinesterases Inhibitors Against Alzheimer’s Disease & Molecular Modeling Studies
Letters in Drug Design & Discovery Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets Positron Emission Tomography in the Diagnosis and Treatment Management of Tuberculosis
Current Pharmaceutical Design Currently Available Methods of Bacterial Cell Detection
Current Immunology Reviews (Discontinued) NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry QSAR as a Random Event: Selecting of the Molecular Structure for Potential Anti-tuberculosis Agents
Anti-Infective Agents Ethambutol Induced Lichenoid Drug Eruption: A Case Report
Current Drug Safety Health Benefits of Ipecac and Cephaeline: their Potential in Health Promotion and Disease Prevention
Current Bioactive Compounds Chromenopyridines: Promising Scaffolds for Medicinal and Biological Chemistry
Current Medicinal Chemistry Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Current Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Current Pharmaceutical Design Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine Editorial (Thematic Issue: Drug Delivery Australia)
Current Drug Delivery Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Using Property Based Sequence Motifs and 3D Modeling to Determine Structure and Functional Regions of Proteins
Current Medicinal Chemistry Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era
Current Drug Metabolism